Humana Inc. (NYSE:HUM) – Investment analysts at Oppenheimer Holdings lifted their Q4 2017 EPS estimates for shares of Humana in a note issued to investors on Wednesday. Oppenheimer Holdings analyst M. Wiederhorn now anticipates that the insurance provider will earn $2.13 per share for the quarter, up from their prior estimate of $1.96. Oppenheimer Holdings has a “Outperform” rating and a $255.00 price target on the stock. Oppenheimer Holdings also issued estimates for Humana’s Q1 2018 earnings at $2.74 EPS, Q3 2018 earnings at $3.58 EPS and Q4 2018 earnings at $2.47 EPS.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to analyst estimates of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same period last year, the company posted $2.30 EPS.

TRADEMARK VIOLATION WARNING: “Brokers Issue Forecasts for Humana Inc.’s Q4 2017 Earnings (NYSE:HUM)” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/07/brokers-issue-forecasts-for-humana-inc-s-q4-2017-earnings-nysehum.html.

A number of other analysts have also weighed in on HUM. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $237.00 price target for the company in a report on Tuesday, April 18th. Jefferies Group LLC lowered shares of Humana from a “buy” rating to a “hold” rating and lowered their price target for the company from $237.00 to $221.00 in a report on Friday, April 21st. Cowen and Company reissued an “outperform” rating and issued a $230.00 price target on shares of Humana in a report on Tuesday, April 25th. Evercore ISI reissued an “outperform” rating and issued a $240.00 price target on shares of Humana in a report on Tuesday, April 25th. Finally, Cantor Fitzgerald raised their price target on shares of Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $241.65.

Large investors have recently modified their holdings of the company. Guardian Life Insurance Co. of America boosted its stake in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the period. Reliance Trust Co. of Delaware boosted its stake in shares of Humana by 0.7% in the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after buying an additional 8 shares during the period. Creative Planning boosted its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock valued at $1,173,000 after buying an additional 15 shares during the period. Cadence Capital Management LLC boosted its stake in shares of Humana by 0.4% in the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock valued at $1,367,000 after buying an additional 22 shares during the period. Finally, Sit Investment Associates Inc. boosted its stake in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock valued at $2,892,000 after buying an additional 40 shares during the period. 99.66% of the stock is currently owned by hedge funds and other institutional investors.

In other Humana news, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now directly owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now directly owns 14,258 shares in the company, valued at $3,421,920. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.